CD8A and lung cancer: Moreover, we found that GB1275 significantly decreases type-2 conventional CD11b+ dendritic cells (cDC2) and significantly increases type-1 CD103+ dendritic cells (cDC1), suggesting an increase in antigen cross-presentation to CD8+ T cells after CD11b modulation (Figures 3G,H and Supplementary Figure 1C), suggesting that the in vivo effects of GB1275 on lung cancer are partly also mediated via increasing the ratio of M1/M2 polarized macrophages in the TME, confirming similar findings in pancreatic cancer models (30).